Bengaluru : Granules India Limited today inaugurated two advanced Centres of Excellence at the Technology Research Park of IIT Hyderabad: the Ascelis Center of Excellence for Peptide Development and Characterization and the Granules Center of Excellence for Particle Engineering.
The inauguration was led by Dr Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India, Mrs. Uma Chigurupati, Executive Director, Granules India Limited & Prof. B S Murty, Director, IITH
Ascelis Center of Excellence for Peptide Development and Characterization, established under Ascelis Peptides, the CDMO arm of Granules, this Centre will drive the development of cosmetic, therapeutic, and pharmaceutical peptides. It is Ascelis’ first development and characterization facility in India and is equipped for primary, secondary, and tertiary structure characterization. The Center brings advanced analytical and process development capabilities in-house and will work in collaboration with our Swiss-based R&D facility Senn Chemicals, strengthening the group’s integrated global peptide offering and reducing reliance on external partners.
Granules Center of Excellence for Particle Engineering, This Centre will advance polymorph research, material science, and novel drug delivery systems, including amorphous solid dispersions. It replaces earlier external and ad-hoc development with a dedicated research platform that enables first-to-file opportunities, enhances formulation performance, and supports the creation of proprietary technologies for regulated markets.
Speaking at the inauguration, Dr Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India, said: “Scientific excellence and rigorous research have always shaped our long-term strategy at Granules. The launch of these Centres of Excellence significantly strengthens our capabilities in peptides and advanced material sciences, areas that will define the next wave of pharmaceutical innovation. With specialised infrastructure and deep scientific expertise, we are enhancing our CDMO ambitions, accelerating breakthrough development, and building differentiated technologies that elevate our global competitiveness and deliver meaningful value to our partners and patients worldwide.”
